Can a drug used to treat chronic fatigue syndrome (CFS) actually prevent it?
Can a therapy that treats chronic fatigue syndromes prevent a disorder from developing in the first place?
That is what scientists at the University of Texas Southwestern Medical Center (UTSSC) are trying to find out with a study published today in the journal Molecular Psychiatry.
“We wanted to study whether a specific drug known as dronabinol could be effective in treating chronic fatigue,” said Dr. Anshuman Gupta, the study’s lead author and a professor in the Department of Psychiatry at UTSSC.
“The main goal was to see if the dronabell could prevent chronic fatigue.”
The study used mice that had been genetically engineered to produce dronolens, which were found to reduce the production of a protein that triggers a variety of genes that contribute to the body’s immune system.
“Our goal was not to look at the genetic code of these mice but to see what happens when we put them into the environment,” said Gupta, who is also an assistant professor in UTSSCC.
“In the lab, we found that dronlens significantly reduced the levels of the protein called TNF-α, which is produced by the immune system and is known to play a role in chronic fatigue.”
The dronein treatment actually caused a dramatic reduction in the levels, which was a very strong signal that drazolens was effective in reducing inflammation in the immune cells,” he added.TNF-alpha is responsible for the production and clearance of other inflammatory molecules that contribute significantly to the development of CFS.”
It was clear that drosophila have a high degree of tolerance for this molecule, which suggests that it may be possible to use dronaens as an alternative treatment,” Gupta said.
This study is the first to demonstrate that dross can be a valuable therapeutic intervention for the treatment of CFF.”
In addition to Gupta and Panchol, the lead authors of the paper are graduate students from UTSSU and the University at Buffalo. “
However, we are excited about the potential of dronas to treat other chronic diseases, and hope that it will eventually be applied in clinical settings.”
In addition to Gupta and Panchol, the lead authors of the paper are graduate students from UTSSU and the University at Buffalo.
The paper is titled, “Dronabinols and the immune response in CFS: A pilot study in mice.”
The UTSS team hopes that their results will be replicated in larger human trials in the future.
In the meantime, Gupta said that he and his colleagues are continuing to study dronazol and other drug candidates to see whether they can be developed as an effective treatment for CFF patients.
“This is a great opportunity to learn how different drugs interact and potentially how they might interact with one another to reduce inflammation in immune cells, thereby reducing the severity of the disease,” he said.